.png){kind=icon}
.png){kind=icon}
Return
Recent progress of large-scale biomarker consortia and paths forward in biomarker development for autism
.png){kind=icon}
PRE
AI
J
B
W
L
A
G
S
S
J
A
J
DOI：10.1016/j.biopsych.2026.08.005.png)
.png){kind=icon}
Original request for help.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
Autism presents significant challenges for clinical research and biomarker development due to behavioral heterogeneity and reliance on clinician- and caregiver-report measures that are limited in sensitivity, objectivity, and scalability. Biomarkers offer a complementary approach by providing biologically grounded, standardized, and potentially more sensitive indicators of the autism phenotype. We outline the potential advantages of biomarkers over traditional clinical assessments, operationalize biomarkers using FDA/NIH consensus frameworks, and evaluate recent progress from large-scale biomarker consortia and remaining challenges for two well-developed measurement modalities: electroencephalography (EEG) and eye-tracking (ET). We summarize findings from one of these recent biomarker consortia, the Autism Biomarkers Consortium for Clinical Trials (ABC-CT), that has established the feasibility, stability, and regulatory relevance of several candidate biomarkers. Despite meaningful advances in reproducibility of biological factors associated with autism, clinically actionable biomarkers remain elusive. We describe potential paths forward to overcome this obstacle, including leveraging neurogenetic syndromes and genomic stratification, aligning biomarkers with biologically specified behavioral constructs, expanding measurement into motor and vestibular domains, and applying data-driven, multimodal, and digital phenotyping approaches to advance clinical trial readiness in autism.
Journal
IF:
9
Papers:
1.5W
Citations:
4.0W
Organization
Cited Papers